Innovative Therapy Collaboration Targeting Acute Pancreatitis for Pets and Humans

A New Hope: Lamassu Biotech Teams with Ohio State University for Dual-Purpose Therapy

Lamassu Biotech, a leading figure in pharmaceutical innovation, has announced an exciting partnership with The Ohio State University to develop a new treatment for acute pancreatitis. This collaboration aims to create effective therapies not only for humans but also for our furry companions—man's best friend.

Acute pancreatitis is a distressing condition that affects countless individuals and animals, leading to over 330,000 hospital admissions among humans each year in the United States, while nearly 1.8 million dogs are impacted. Currently, there are no effective treatments available in either field, making this collaboration crucial in addressing a significant medical challenge. By bridging the gap between human and veterinary medicine, Lamassu Biotech and The Ohio State University are poised to optimize treatment strategies that could provide solutions for both species.

At the foundation of this research is RABI-767, an innovative therapeutic targeting acute pancreatitis, which Lamassu Biotech has been developing in conjunction with the Mayo Clinic. Preclinical studies have shown promising results, demonstrating potential for significantly reducing the mortality and morbidity rates related to severe acute pancreatitis. With a focused strategy on using an injection delivered directly around the pancreas, the goal is to improve patient outcomes by managing symptoms more effectively, minimizing complications, and safeguarding against organ failure.

The trials aim to explore various dosing schedules for RABI-767 that could enhance its efficacy in dogs. The first of these canine trials is on the horizon, with Gabi Hanna, MD, CEO of Lamassu Biotech, expressing enthusiasm about the potential benefits this research could yield: “This is an exciting development for those suffering from acute pancreatitis and our four-legged family members who might also be affected.”

The collaboration harnesses the expertise of The Ohio State University Veterinary Medical Center, recognized among the largest and most reputable institutions for overseeing clinical trials concerning naturally occurring diseases in animals. Adam Rudinsky, DVM, from the Department of Veterinary Clinical Sciences, highlighted the importance of these trials: “A clinical trial targeting acute pancreatitis in pets is crucial for enhancing veterinary treatment while also benefiting human healthcare through translational medicine.”

As part of this collaborative effort, Lamassu Biotech has formally launched a new division known as Lamassu Pets, dedicated to the global development of canine-specific drugs based on the RABI-767 treatment. This initiative is aligned with Lamassu's mission to bring innovative solutions to market that provide hope and healing for patients and their families.

In addition to its focus on veterinary medicine, Lamassu Biotech is advancing human clinical trials for RABI-767, currently in phase 2, in partnership with Arrivo Bioventure. This comprehensive approach ensures a synergistic development process that allows knowledge gained from canine studies to inform human applications, ultimately accelerating the path toward effective treatment solutions.

While more details regarding the canine-focused trial are awaited, this partnership is a testament to the potential that innovation, collaboration, and a commitment to improving health outcomes can realize. The convergence of human and veterinary medicine may lead to revolutionary advancements, transforming the treatment landscape for both dogs and their human companions alike.

For more information about Lamassu Biotech's initiatives and ongoing research, visit their website at LamassuBioTech.com.